Jiaxin Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiaxin Liu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Gang Yin
Department of Pathology, Xiangya Hospital, School of Basic Medical Sciences, Central South University, Changsha, China
2 shared publications - Guang Shu
Department of Pathology, Xiangya Hospital, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China
2 shared publications AiLin Li
Xiangya School of Basic Medical Sciences, Central South University, Changsha, China
1 shared publicationChang Liu
Xiangya School of Medicine, Central South University, Changsha, China
1 shared publicationDi Wu
Department of Pathology, Xiangya Hospital, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China
1 shared publicationHanxi Yi
Department of Pathology, Xiangya Hospital, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China
1 shared publication
Latest Publications
- Open Access
- 14 March 2026
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (11) , 2220-2235
Ubiquitination of MEIS1 by MDM2 serves as a switch for p53 stabilization and DNA damage response activation
Targeting MDM2 by disrupting its interaction with p53 or inhibiting its E3 ligase activity is a promising strategy to restore p53 functionality. However, achieving anticancer efficacy while minimizing dose-limiting toxicities remains a significant challenge. Moreover, MDM2 also ubiquitinates various non-p53 targets, complicating its therapeutic targeting. In this study, we demonstrate that MDM2 directly facilitates K48-linked polyubiquitination of MEIS1 at K178, leading to its proteasomal degradation. Notably, MEIS1 forms a non-competitive ternary complex with MDM2 and p53, effectively promoting ubiquitin transfer to itself and preventing p53 ubiquitination. The MEIS1 K178R mutant, which is deficient in ubiquitination, fails to suppress MDM2-mediated p53 ubiquitination, demonstrating a mechanistic link between MEIS1 self-ubiquitination and p53 stabilization. Furthermore, MDM2-mediated MEIS1 ubiquitination is a prerequisite for p53 activation in the DNA damage response. Importantly, a MEIS1-derived peptide, which mimics the MDM2-mediating ubiquitination motif, enhances both MEIS1 and p53 stability, suppresses cell proliferation and tumor growth. Collectively, our findings identify MEIS1 as a molecular decoy that competes for ubiquitin transfer to protect p53 and highlight that MEIS1 ubiquitination could be a novel therapeutic target for reactivating p53-dependent tumor suppression.
- 14 March 2026
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (11) , 2220-2235
Open AccessUbiquitination of MEIS1 by MDM2 serves as a switch for p53 stabilization and DNA damage response activation
Targeting MDM2 by disrupting its interaction with p53 or inhibiting its E3 ligase activity is a promising strategy to restore p53 functionality. However, achieving anticancer efficacy while minimizing dose-limiting toxicities remains a significant challenge. Moreover, MDM2 also ubiquitinates various non-p53 targets, complicating its therapeutic targeting. In this study, we demonstrate that MDM2 directly facilitates K48-linked polyubiquitination of MEIS1 at K178, leading to its proteasomal degradation. Notably, MEIS1 forms a non-competitive ternary complex with MDM2 and p53, effectively promoting ubiquitin transfer to itself and preventing p53 ubiquitination. The MEIS1 K178R mutant, which is deficient in ubiquitination, fails to suppress MDM2-mediated p53 ubiquitination, demonstrating a mechanistic link between MEIS1 self-ubiquitination and p53 stabilization. Furthermore, MDM2-mediated MEIS1 ubiquitination is a prerequisite for p53 activation in the DNA damage response. Importantly, a MEIS1-derived peptide, which mimics the MDM2-mediating ubiquitination motif, enhances both MEIS1 and p53 stability, suppresses cell proliferation and tumor growth. Collectively, our findings identify MEIS1 as a molecular decoy that competes for ubiquitin transfer to protect p53 and highlight that MEIS1 ubiquitination could be a novel therapeutic target for reactivating p53-dependent tumor suppression.
- Open Access
- 2 March 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (3) , 1-14
Metformin suppresses the growth of colorectal cancer by targeting INHBA to inhibit TGF-β/PI3K/AKT signaling transduction
Multiple evidence shows that metformin serves as a potential agent for Colorectal Cancer (CRC) treatment, while its molecular mechanisms still require detailed investigation. Here, we revealed that metformin specifically suppressed the proliferation of CRC cells by causing G1/S arrest, and INHBA is a potential target for metformin to play an anti-proliferation effect in CRC. We verified the oncogene role of INHBA by knocking down and overexpressing INHBA in CRC cells. Silencing INHBA abrogated the cell growth, while overexpression INHBA promotes the proliferation of CRC cells. As an oncogene, INHBA was aberrant overexpression in CRC tissues and closely related to the poor prognosis of CRC patients. In mechanism, INHBA is an important ligand of TGF-β signaling and metformin blocked the activation of TGF-β signaling by targeting INHBA, and then down-regulated the activity of PI3K/Akt pathway, leading to the reduction of cyclinD1 and cell cycle arrest. Together, these findings indicate that metformin down-regulates the expression of INHBA, then attenuating TGF-β/PI3K/Akt signaling transduction, thus inhibiting the proliferation of CRC. Our study elucidated a novel molecular mechanism for the anti-proliferation effect of metformin, providing a theoretical basis for the application of metformin in CRC therapy.
- 2 March 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (3) , 1-14
Open AccessMetformin suppresses the growth of colorectal cancer by targeting INHBA to inhibit TGF-β/PI3K/AKT signaling transduction
Multiple evidence shows that metformin serves as a potential agent for Colorectal Cancer (CRC) treatment, while its molecular mechanisms still require detailed investigation. Here, we revealed that metformin specifically suppressed the proliferation of CRC cells by causing G1/S arrest, and INHBA is a potential target for metformin to play an anti-proliferation effect in CRC. We verified the oncogene role of INHBA by knocking down and overexpressing INHBA in CRC cells. Silencing INHBA abrogated the cell growth, while overexpression INHBA promotes the proliferation of CRC cells. As an oncogene, INHBA was aberrant overexpression in CRC tissues and closely related to the poor prognosis of CRC patients. In mechanism, INHBA is an important ligand of TGF-β signaling and metformin blocked the activation of TGF-β signaling by targeting INHBA, and then down-regulated the activity of PI3K/Akt pathway, leading to the reduction of cyclinD1 and cell cycle arrest. Together, these findings indicate that metformin down-regulates the expression of INHBA, then attenuating TGF-β/PI3K/Akt signaling transduction, thus inhibiting the proliferation of CRC. Our study elucidated a novel molecular mechanism for the anti-proliferation effect of metformin, providing a theoretical basis for the application of metformin in CRC therapy.